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Abstract 
 
Patients with a left ventricular assist device (LVAD) commonly encounter issues 
with volume status post-implant. Volume overload can result from incomplete 
compensation of left ventricular failure or from right ventricular failure. The 
CardioMEMS™ intracardiac hemodynamic monitoring device is an area of growing 
interest regarding the management of chronic congestive heart failure, however, 
its utility has not been serially investigated in patients with an LVAD. We present a 
case series of patients with ventricular assist devices care for at our institution in 
which the CardioMEMS™ device aided in the management of volume status and 
pump performance. 
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Introduction 
 
As decompensated heart failure (HF) represents a leading cause for 
hospitalization and carries a high readmission rate, it imposes high economic 
burdens on health care organizations.  As such, prediction of decompensation has 
been a surging area of interest.  Patients randomized to treatment guided by 
pulmonary artery pressure data from theCardioMEMS™ (St. Jude Medical, Inc., 
St. Paul, MN) device reduced their HF-related hospitalizations at six months, 
garnering much enthusiasm regarding intracardiac hemodynamic monitoring1. 
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The utility of the CardioMEMS™ device, however, has not been investigated in 
patients with a left ventricular assist device (LVAD), a population which also 
carries a high readmission rate after implantation.  Hospital                               
readmissions in LVAD patients occur at a rate of 1.5-2.5 per patient year of   
support with HF representing a leading cause 2-4.  Persistent heart failure after 
LVAD implantation is common, occurring in up to 25% of patients5.  Such 
persistence of HF may result from incomplete compensation of left ventricular (LV) 
failure or from right ventricular (RV) failure. 
 
Given the lack of available data, we retrospectively reviewed the LVAD patient 
population managed at our institution who had a CardioMEMS™ device implanted.  
We present a case series of four patients whose volume status we managed by 
relying on the information made available by the CardioMEMS™ device.  None of 
the patients had any complications related to the CardioMEMS™ device 
implantation procedure 
 
Case Series 
Patient 1 
A 52-year-old male had multiple admissions after implantation of a HeartWare 
LVAD in the beginning of 2014 for nonischemic cardiomyopathy.  He never had 
any serious complications of the LVAD (such as infections or bleeding) but was 
admitted nearly monthly (16 admissions over 2 years).  The majority of admissions 
related to complaints of weight gain, increased abdominal girth, and peripheral 
edema.  His volume status was difficult to evaluate clinically as the patient was 
morbidly obese with a body mass index of 43.  After implantation of the 
CardioMEMS™ device, he was admitted twice over an eight month follow-up 
period with no admissions in the latter six months.  There were a total of 22 
adjustments in his diuretic dose afterCardioMEMS™ implantation.  Prior to 
CardioMEMS™, the patient was taking bumetanide 2 mg/day with metolazone as 
needed.  At the time when data was collected for this report, his dose was 
bumetanide 4 mg/day and metolazone 5 mg/day.  The patient serum creatinine 
improved from 2.8 mg/dL to 1.3 mg/dL.  His pump speed was also adjusted 
several times and ultimately increased from 2900 revolutions per minute (rpms) 
before CardioMEMS™ implantation, to 3000 rpms currently.  There was no 
significant change in his pulmonary artery pressures. 
 
Patient 2 
 
A 52-year-old male with nonischemic cardiomyopathy had a HeartMate II LVAD in 
place for five months before a CardioMEMS™ was implanted.  In the four months 
after CardioMEMS™ implantation, his pulmonary arterial pressures decreased 
from 38/20 mmHg to 32/16 mmHg.  There were 18 diuretic dose adjustments.  The 
patient’s baseline dose was torsemide 40 mg/day while his current dose is 
 
 
 
 
The VAD Journal: http://dx.doi.org/10.13023/VAD.2016.21 Page 3 of 6 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
torsemide 40 mg/day with metolazone 5 mg/day.  His pump  speed was increased 
from 9600 rpms to 9800 rpms.  Serum creatine decreased from 2.4 mg/dL to 1.6 
mg/dL.  Nevertheless, the patient continued to have marked peripheral edema, 
likely related to right ventricular failure, and is currently listed for heart 
transplantation. 
 
Patient 3 
 
A 66-year-old male with nonischemic cardiomyopathy was implanted with a 
CardioMEMS™ device after seven months of HeartMate II LVAD support.  Prior to 
this, the patient had four admissions related to either gastrointestinal bleeding or 
volume overload.  While on CardioMEMS™ monitoring over four months, he was 
admitted once.  His pulmonary arterial pressures were near normal over this 
period of time.  His diuretic dose, however, was adjusted six times, changing from 
torsemide 80 mg/day to torsemide 40 mg/day.  His serum creatinine has slowly 
trended down from 2.98 mg/dL to 2.88 mg/dL. 
 
Patient 4 
 
A 60-year-old male was implanted with a HeartMate II LVAD in the spring of 2015.  
Within 11 months, the patient had 3 admissions, 2 of which primarily related to 
gastrointestinal bleeding.  However, his function status remained limited and 
symptoms were consistent with either volume overload (edema, weight gain) or 
with volume depletion (dizziness).  He subsequently underwent CardioMEMS™ 
implantation and in the following five months, there was only one admission.  His 
pulmonary arterial pressure decreased from 40/20 mmHg to 37/16 mmHg.  A total 
of 11 diuretic adjustments were made.  His torsemide dose was gradually 
decreased from 40 mg/day to 20 mg every other day along with metolazone 2.5 
mg.  Serum creatinine improved from 2.1 mg/dL to 1.7 mg/dL. 
 
A summary of the 4 patients along with important clinical and hemodynamic trends 
can be found in Tables 1 and 2.  
 
Table 1: Summary of patients with LVAD after CardioMEMS™ implantation 
Patient and Device Age 
Months between 
LVAD 
implantation and 
CardioMEMS™  
Months of data 
collection with 
CardioMEMS™  
Number of 
diuretic 
adjustments with 
CardioMEMS™  
Patient 1 - HeartWare 52 23 7 22 
Patient 2 - HeartMate II 52 5 4 18 
Patient 3 - HeartMate II 66 7 4 6 
Patient 4 - HeartMate II 60 11 5 11 
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Table 2: Hemodynamic and clinical changes before and after CardioMEMS™ 
implantation 
Patient
Before After Before After Before After Before After Before After Before After
Patient 1
41.4 ± 
5.2
42.1 ± 
3.8
21.7 ± 
1.8
21.8 ± 
2.5
2.8 1.3 2900 3000 0.7 0.3
Bumex 2 + 
metolazone 5
Bumex 4 + 
metolazone 5
Patient 2
38.1 ± 
3.0
32 ± 
2.6*
19.7 ± 
1.9
15.6 ± 
1.6*
2.43 1.64 9600 9800 0.8 0.5 Torsemide 40  
Torsemide 40 + 
metolazone 5  
Patient 3
34.9 ± 
4.6
35.5 ± 
3.0
14.4 ± 
2.9
13.2 ± 
1.3***
2.98 2.88 9600 9600 0.6 0.25 Torsemide 40 Torsemide 20
Patient 4
40.5 ± 
5.6
37.5 ± 
7.4
20.1 ± 
3.3
16.3 ± 
3.5**
2.1 1.7 9200 9200 0.27 0.2 Torsemide 40  
Torsemide 10 + 
metolazone 1.25`
PASP - pulmonary artery systolic pressure, PADP - pulmonary artery diastolic pressure, RPMS - revolutions per minute
*p < 0.0001,     **p = 0.0009,     ***p = 0.047
Mean PASP
(mmHg)
Mean PADP
(mmHg)
Serum 
creatinine
(mg/dL)
Pump speed
(rpms)
Number of 
admissions/month
Diuretic dose
(mg/day)
 
 
Discussion 
 
Left ventricular assist devices improve hemodynamics in advanced HF by 
increasing LV output.  Nevertheless, as many as 20-25% of patients may have HF 
after LVAD implantation, due to either incomplete compensation of LV failure or 
from the presence of RV failure5.  Persistent fluid retention, in either the pulmonary 
or systemic circulation (or both), requires diuretics.  In fact, it has been our 
experience that roughly half of the patients on LVAD support continue taking loop 
diuretics, even if it is on an as needed basis. 
 
Right heart catheterization in LVAD patients revealed that only 43% of patients 
had a normal central venous pressure and pulmonary capillary wedge pressure.  
Optimization of pump parameters under hemodynamic control results in significant 
improvement in both cardiac output and wedge pressure and achieved nearly 
normal hemodynamics in 56% of patients6.  Not surprisingly, several abstracts at 
the 2016 International Society for Heart and Lung Transplant meeting presented 
novel ways to diagnose fluid overload in patients on LVAD support.Specifically, 
Grinstein et al found that that analyzing the ventricular phase slope in a HeartWare 
device can determine elevated pulmonary capillary wedge pressure and 
decreased cardiac output7.  Moss et al discovered that changes in LV pacing lead 
impedance also correlated with changes in wedge pressure during hemodynamic 
ramp tests8. 
 
At our institution, we believe that utilizing already existing technology for remote 
hemodynamic monitoring, namely CardioMEMS™, affords several advantages.  
Not only is there easy access to key hemodynamic parameters on a regular basis, 
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but less time and effort are needed to perform echocardiogram ramp tests or 
placement of a Swan-Ganz catheter. 
 
In our small case series, we demonstrated that in three out of four patients, 
pulmonary arterial diastolic pressures significantly decreased after just a few 
months of post-implant monitoring.  This is particularly remarkable, because due to 
financial regulation, the CardioMEMS™ device is typically not implanted when the 
patient is already admitted for fluid overload.  In fact, the device is implanted when 
subjects are in a stable status, i.e. in the outpatient setting.  As a result, pulmonary 
arterial pressures are near normal to begin with and further reduction was difficult 
to achieve.  Likewise, conveying statistical significance is impossible with a mere 
four cases, however all patients invariably had fewer admissions after 
CardioMEMS™ implantation.  As important is the fact that all four patients 
experienced some improvement in serum creatinine. 
 
Volume status with LVAD patients can be controlled by changing loop diuretic 
dose and/or adjusting pump speed.  Analysis of the CHAMPION trial demonstrated 
that diuretics were adjusted many more times in patients with CardioMEMS™ 
when providers had access to hemodynamic data as compared to a control 
group1.  We made multiple adjustments of diuretics in our patients.  Unfortunately, 
the documentation of changes was not as thorough before CardioMEMS™ 
implantation and a comparison of the number of changes was not feasible. 
Finally, one of the patients in our case series failed to improve with remote 
hemodynamic monitoring because of severe RV failure.  Pulmonary arterial 
pressured measured by the CardioMEMS™ device reflects the degree of LV 
failure.  Elevations in central venous pressure, the hallmark of RV failure, cannot 
be detected.  As such, the evaluation of RV failure requires a different means of 
diagnosis. 
 
Future studies regarding the role of the CardioMEMS™ device in LVAD patients 
should focus on collecting and analyzing the following several pieces of data.  
Hemodynamic parameters of right heart catheterization before LVAD implantation 
and before subsequent CardioMEMS™ implantation would be particularly 
beneficial as it allows for two sets of invasive hemodynamics (in steady state and 
during volume overload).  Second, the number and magnitude of pump speed 
adjustments before and after CardioMEMS™ implantation should be tracked.  
Also, the number of diuretic adjustments (agents and doses) should be 
characterized before and after CardioMEMS™ implantation.  Lastly, the number 
and causes of hospitalizations before and after CardioMEMS™ implantation 
should be described. 
 
Conclusion 
 
Our case series of patients on long-term LVAD support with concomitant remote 
hemodynamic monitoring using the CardioMEMS™ device demonstrated 
favorable profiles including a decrease in pulmonary artery diastolic pressures, 
improvement in serum creatinine levels, and a trend to fewer hospital 
readmissions.  An observational study with a larger cohort and longer follow-up 
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period, but especially a randomized, controlled trial would be necessary to validate 
the utility of remote hemodynamic monitoring with the CardioMEMS™  device in 
this unique patient population. 
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